Diagnostic value and clinical significance of serum CD26 in papillary thyroid carcinoma
-
摘要:
目的 探讨血液中可溶性CD26（soluble CD26，sCD26）对于甲状腺乳头状癌（papillary thyroid carcinoma，PTC）诊断的价值及其临床意义。 方法 收集2013年1月至2017年12月天津医科大学总医院行手术治疗的104例PTC患者临床病例资料，同期行手术治疗的甲状腺良性肿瘤患者25例及健康人群55例作为对照组。分别收集各组空腹血液样本，应用ELISA法测定sCD26浓度，记录PTC患者的临床病理特征，分析sCD26浓度对PTC的诊断价值及其与临床病理特征的关系。 结果 PTC患者术前sCD26浓度升高，与良性病变组和健康对照组比较呈显著性差异（P < 0.05）；术后sCD26浓度下降，与术前比较呈显著性差异（P < 0.05），与良性病变组和健康对照组无显著性差异（P>0.05）。以sCD26区分PTC与甲状腺良性病变的敏感性、特异性、诊断准确率分别为75.50%、91.21%、85.00%，最佳诊断界值为545.20 ng/mL。经χ2检验，sCD26高浓度与PTC患者肿瘤大小≥4.0 cm和临床分期Ⅲ期呈显著性差异（均P < 0.05），与性别、年龄、淋巴结转移、肿瘤包膜侵犯、术前TI-RADS分级均无显著性差异（均P>0.05）。 结论 sCD26浓度对PTC有一定诊断价值，可能是PTC预后的独立预测指标。 Abstract:Objective To investigate the value and clinical significance of soluble CD26 (sCD26) in blood in the diagnosis of papillary thyroid carcinoma (PTC). Method A total of 104 PTC patients who had undergone surgery at the Tianjin Medical University General Hospital from January 2013 to December 2017 were collected as the study group. In the study period, surgery had been performed for 25 cases of a benign thyroid lesion, who served as control group. The control also group included 55 cases that had undergone health examination. The fasting blood samples of the PTC group before and after the operation and those of the control group were collected. The sCD26 concentration was determined by ELISA. Clinical pathology features of PTC patients were recorded to analyze the diagnostic value of the sCD26 concentration on PTC and its relationship with clinicopathological features. Results The preoperative sCD26 concentration in PTC patients increased and significantly differed from the control groups. The sCD26 concentration had significantly decreased postoperatively compared to the preoperative value but showed no significant difference from the control group. The sensitivity, specificity, diagnostic accuracy, and optimal diagnostic boundary values for sCD26 distinguishing thyroid carcinoma from benign thyroid lesions were 75.50%, 91.21%, 85.0%, and 545.20 ng/mL, respectively. The results of the chi-square test showed a significant correlation of the high concentration of sCD26 with the tumor size ≥4.0 cm and clinical stage Ⅲ in patients with PTC, but there was no significant correlation with the sex, age, lymph node metastasis, tumor capsule invasion, or preoperative TI-RADS classification. Conclusions The sCD26 concentration has a diagnostic value for PTC and may be an independent predictor of the PTC prognosis. -
Key words:
- soluble CD26 (sCD26) /
- papillary thyroid carcinoma (PTC) /
- diagnosis /
- prognosis
-
表 1 PTC患者术前sCD26浓度与临床病理指标的相关性
-
[1] Qiu Y, Fei Y, Liu J, et al. Prevalence, risk factors and location of skip metastasis in papillary thyroid carcinoma:a systematic review and meta-analysis[J]. Cancer Manag Res, 2019, 25(11):8721-8730. http://www.researchgate.net/publication/336047643_Prevalence_Risk_Factors_And_Location_Of_Skip_Metastasis_In_Papillary_Thyroid_Carcinoma_A_Systematic_Review_And_Meta-Analysis [2] 王晶, 刘龙腾, 崔娣, 等.BRAF V600E突变与甲状腺乳头状癌发生及预后相关因素分析[J].中华病理学杂志, 2019, 48(4):288-292. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhblx201904006 [3] 王天笑, 宋韫韬, 徐国辉, 等.细针穿刺技术在甲状腺乳头状癌侧颈淋巴转移中的预测价值[J].中华耳鼻咽喉头颈外科杂志, 2019, 54(1):23-27. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhebyhk201901006 [4] Mahmoudian-Sani MR, Mehri-Ghahfarrokhi A, Asadi-Samani M, et al. Serum miRNAs as biomarkers for the diagnosis and prognosis of thyroid cancer:a comprehensive review of the literature[J]. Eur Thyroid J, 2017, 6(4):171-177. http://www.ncbi.nlm.nih.gov/pubmed/28868257 [5] 常伟, 韩星敏, 刘保平, 等.老年甲状腺癌患者手术临床疗效和预后分析[J].中华老年医学杂志, 2018, 3(10):1115-1117. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhlnyx201810013 [6] Beckenkamp A, Davies S, Willig JB, et al. DPPIV/CD26:a tumor suppressor or a marker of malignancy[J]? Tumour Biol, 2016, 37(6):7059-7073. http://www.ncbi.nlm.nih.gov/pubmed/26943912 [7] Ohnuma K, Hatano R, Komiya E, et al. A novel role for CD26/dipeptidyl peptidase Ⅳ as a therapeutic target[J]. Front Biosci (Landmark Ed), 2018, 1(23):1754-1779. [8] Enz N, Vliegen G, De Meester I, et al. CD26/DP:4-a potential biomarker and target for cancer therapyt[J]. Pharmacol Ther, 2019, 198:135-159. http://www.ncbi.nlm.nih.gov/pubmed/30822465 [9] Davies S, Beckenkamp A, Buffon A. CD26 a cancer stem cell marker and therapeutic target[J]. Biomed Pharmacother, 2015, 71:135-138. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=4856252d5b02460125af6c9637d92932 [10] Havre PA, Abe M, Urasaki Y, et al. The role of CD26/dipeptidyl peptidase IV in cancer[J]. Front Biosci, 2008, 1(13):1634-1645. http://www.ncbi.nlm.nih.gov/pubmed/17981655 [11] Kwak JY, Han KH, Yoon JH, et al. Thyroid imaging reporting and data system for US features of nodules:a step in establishing better stratification of cancer risk[J]. Radiology, 2011, 260(3):892-899. http://www.ncbi.nlm.nih.gov/pubmed/21771959 [12] 赵群仔, 王勇, 王平.腔镜与开放甲状腺全切除术治疗乳头状甲状腺癌的对比研究[J].中华外科杂志, 2018, 56(2):135-138. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhwk201802011 [13] Kruijff S, Petersen JF, Chen P, et al. Patterns of structural recurrence in papillary thyroid cancer[J]. World J Surg, 2014, 38(3):653-659. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=abdd3cd1a5051e313258505507e2de61 [14] 张磊, 杨进宝, 孙庆贺.cN0甲状腺微小乳头状癌多个淋巴结转移的危险因素分析[J].中国肿瘤临床, 2017, 44(16):805-809. http://journal11.magtechjournal.com/Jwk_zgzllc/CN/abstract/abstract13682.shtml [15] Kwong N, Marqusee E, Gordon MS, et al. Long-term, treatment-free survival in select patients with distant metastatic papillary thyroid cancer[J]. Endocr Connect, 2014, 3(4):207-214. http://europepmc.org/abstract/MED/25316293 [16] 徐乐, 徐雅男, 王家东.甲状腺乳头状微小癌3607例淋巴结转移及生存率相关因素分析[J].中华耳鼻咽喉头颈外科杂志, 2017, 52(4):267-272. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhebyhk201704006 -
点击查看大图
表(1)
计量
- 文章访问数: 147
- HTML全文浏览量: 26
- PDF下载量: 4
- 被引次数: 0
下载:
